

**Ask Me Anything About My Career with AAPS Leaders**

Are you considering a career path in academia, industry, or nonprofits? Join four panelists with diverse backgrounds and expertise who are working today in academia, nonprofits, industry, and contract research organizations. They will share their personal journeys and then take questions from AMA participants in the AAPS Community. They will help you map out an approach to jobs in academia, nonprofits, industry, and CROs, including identifying and developing necessary skill sets. They'll also highlight the challenges and opportunities of each field. Bring your tough questions and expect insightful answers from conversation with President Annette Bak, Ph.D., FAAPS; President-elect Patrick Sinko, Ph.D., FAAPS; Immediate Past President Andrew Vick, Ph.D.; and Executive Director Tina Morris, Ph.D. This is your chance to ask anything!

Live, 1-hour discussion thread in the AAPS Community

Date: February 14, 2022 from 3 - 4 pm EST.

Meet the expert panelists:**Annette Bak, Ph.D., M.B.A., FAAPS**

Annette Bak, Ph.D., MBA leads Advanced Drug Delivery at Astra Zeneca and serves on the Pharmaceutical Sciences leadership team. Advanced Drug Delivery has the mission to transform diverse modalities, small molecules and new modalities alike, into investigational medicines and is a global organization based in Sweden, UK, and US.

Since joining AstraZeneca in 2016, Annette has been instrumental in delivering new modality formulations for clinical studies, notably VEGF mRNA for cardiac regeneration, building intracellular drug delivery capabilities, and sponsoring initiatives on augmenting drug discovery with artificial intelligence. Annette previously worked for Amgen and Merck in the US with responsibility for small molecule and peptide formulations, building outsourcing partnerships in China, in licensing and partnership evaluations, and contributing to getting small molecule therapies to the market. Annette has published more than 40 articles, has more than 35 invited presentations, and serves on the editorial board for the Journal of Pharmaceutical Sciences. She holds several patents for pharmaceutical technologies enabling drug delivery of small molecules and biologics.

A key volunteer in American Association of Pharmaceutical Scientists (AAPS). She is the President for the association and responsible for leading implementation of the 2021-2025 strategic plan and ensuring that the AAPS communities are thriving. Annette was the 2020 co-recipient of the AAPS Alice E Till Women in Pharmaceutical Science Recognition, honoring women who has made significant contributions to the to the mentorship, advancement, and support of women in the pharmaceutical sciences.

**Tina Morris, Ph.D.**

Dr. Morris is the Executive Director of the American Association of Pharmaceutical Scientists (AAPS). She leads the staff team that supports all operational aspects of the Association and works with the AAPS Board of Directors and other Volunteer Leadership Committees on the strategic and direction-setting activities that guide the work of the scientific society. Prior to that, she was Vice President of Scientific and Regulatory Affairs at the Parenteral Drug Association (PDA). Until 2018, Dr. Morris held several scientific senior leadership positions at the United States Pharmacopeia (USP), including as the Global Head of Biologics and Senior Vice President of Compendial Science. Before joining USP in 2003, Dr. Morris worked in the biopharmaceutical industry, with an expertise focus on analytical development and product characterization. She completed her postdoctoral research at the National Institutes of Health. She holds a Ph.D. in molecular virology from the Medical University of Lübeck, Germany, and a master's degree in biology from the Carl von Ossietzky University of Oldenburg, Germany.

**Patrick J. Sinko, Ph.D., R.Ph., FAAPS**

Dr. Patrick J. Sinko is a Distinguished Professor and the Parke-Davis Endowed Chair in Pharmaceutics and Drug Delivery in the Ernest Mario School of Pharmacy, Rutgers University where he also served as Chair of the Department of Pharmaceutics from 1998-2008. From 2007 to 2018, Dr. Sinko served as Associate Vice President for Research in the Office Research and Economic Development covering all three regional campuses where he founded and led the Office of Research Advancement, providing executive-level oversight of Comparative Medicine Resources, Core Research Services, Biomedical Advisory Committees, and the Controlled Substances program. Dr. Sinko was a co-Founder and Chief Scientist for three companies including Navicyte, Inc, which was acquired by Trega Biosciences (NASDAQ: TRGA) where he also served as the Vice President for Discovery Technologies.

Dr. Sinko is the Editor of Martin's Physical Pharmacy and Pharmaceutical Sciences (Fifth, Sixth, Seventh, and Eighth Editions) and is on the Editorial Advisory Board of numerous journals. He is the Editor-in-Chief (Biopharmaceutics) for Pharmaceutics. Dr. Sinko has authored or coauthored over 475 publications, given over 175 invited lectures, and is listed as an inventor on 20 issued patents. He has trained ~90 MS/PhD students and post-graduate scientists. Dr. Sinko is the Principal Investigator of an active research laboratory that focuses on biopharmaceutics, pharmaceutical formulations, and molecular-, nano- and micro-scale drug delivery with specific applications to treat or prevent HIV/AIDS, breast, and lung cancer, and chemical terrorism countermeasures. The NIH has continuously funded his lab for over 30 years. During his career, Dr. Sinko has received several awards for his teaching and research, including the Rutgers University Board of Trustees Award for Excellence in Research and highly selective National Institutes of Health FIRST and MERIT Awards.

**Andrew M. Vick, Ph.D.**

Dr. Andrew Vick has over 23 years of experience working within the biotechnology and pharmaceutical industry in the fields of toxicology, nonclinical and clinical pharmacology, and drug disposition. Currently, Dr. Vick is responsible for creating and executing long-term strategic sales plan for all Charles River Laboratories products and services for large target accounts which are of significant strategic importance to the organization in order to increase market penetration/share, improve customer satisfaction, and improve sales growth. Previously, Dr. Vick was responsible for financial, operational, and scientific oversight of all Midwest sites within Charles River's North American Safety Assessment business.

Prior to joining Charles River, Dr. Vick was Vice President, Analytical Services for WIL Research, overseeing scientific and operational aspects of the analytical, formulations, bioanalytical, metabolism, and pharmacokinetic services for the sites in the US. Prior to WIL Research, he was Executive Vice President and Senior Director of Pharmacokinetics, Dynamics, and Metabolism at Seventh Wave Laboratories. Previous roles have included: Scientific Director of the BioPharma Services Division of Millipore, Principal Scientist within the Drug Disposition and Toxicology department of Eli Lilly and Company, and a preclinical scientist at Biogen.

Dr. Vick earned his B.S. in Zoology and Ph.D. in Pharmaceutical Chemistry from The Ohio State University. He has continued his support of the University through service on the Dean's Corporate Council for the College of Pharmacy, and he serves the Division of Pharmaceutical Chemistry as an Adjunct Professor. Dr. Vick also serves in the role of Immediate Past President for the American Association of Pharmaceutical Scientists.

